Peripheral primitive neuroectodermal tumour – a rare cause of a popliteal fossa mass: A case report and review of the literature

Colin M Davis MBBS¹, Andrew MTL Choong MBBS^{2,3}, David Sharp MBBS¹,
Touraj Taheri MD FRCPA⁴, Shireen Senewiratne MBBS FRACS¹, Vedella Hinckley MBBS FRACS¹

CM Davis, AMTL Choong, D Sharp, T Taheri, S Senewiratne, V Hinckley. Peripheral primitive neuroectodermal tumour – a rare cause of a popliteal fossa mass: A case report and review of the literature. *Plast Surg* 2014;22(3):207-210.

A literature review of peripheral primitive neuroectodermal tumours, illustrated with an index case report describing an 80-year-old woman who presented with a mass in the left popliteal fossa, is reported. An excision biopsy was performed, revealing a possible peripheral primitive neuroectodermal tumour as the primary pathology. Normally confined to the chest wall and axial soft tissues of children and young adults, reports of this tumour existing in other areas and in the elderly population are scarce.

Key Words: Ewing sarcoma; PNET; Primitive neuroectodermal tumour; Small round cell tumour

CASE PRESENTATION

An active 80-year-old woman presented to her local doctor with a lesion in her left popliteal fossa. The patient had no history of trauma to the area, no pain from the lesion and, aside from some discomfort due to the lesion's location and tendency to bleed, experienced no other local or systemic symptoms. First noticed by the patient in mid December as a hard blood blister, the lesion grew rapidly and, when it was excised in early February, it measured 25 mm × 23 mm. Initial histopathology described it as a neoplastic infiltrate involving dermis and subcutis of uncertain histogenesis. A computed tomography scan of her chest, abdomen and pelvis was conducted in mid February, which showed no evidence of metastatic disease. Due to the uncertainty of the diagnosis, the patient was referred to a tertiary centre for expert opinion. In early March, following specialized staining tests, a supplementary pathology report was issued favouring the lesion as a malignant small round-cell tumour consistent with primitive neuroectodermal tumour (PNET). Clinical examination by the radiation oncology team in March suggested local recurrence that was confirmed with a positron emission tomography scan, focal lymphadenopathy and, additionally, two suspicious lung lesions. Re-excised in April by the plastics and reconstructive surgical team, the visible lesion had regrown to approximately 70 mm in length (Figure 1).

Intraoperatively, the exophytic mass was found to have a large subcutaneous compartment, tracking between the muscles both proximally and distally. Due to the depth of its involvement with the neurovascular bundles, clear margins were unable to be obtained. A repeat computed tomography scan performed postoperatively showed 25 new soft tissue nodules throughout the lungs with bulky hilar lymphadenopathy. The two lesions observed on the positron emission tomography scan one month earlier had grown dramatically, one growing from 9 mm to 25 mm. No lesions were noted elsewhere.

La tumeur neuroectodermique primitive périphérique – une rare cause de masse du creux poplité : rapport de cas et analyse bibliographique

Une analyse bibliographique des tumeurs neuroectodermiques primitives périphériques est présentée conjointement à un cas de référence décrivant une femme de 80 ans qui a consulté à cause d'une masse du creux poplité gauche. Une excision-biopsie a révélé la possibilité d'une tumeur neuroectodermique primitive périphérique en pathologie primaire. Normalement, cette tumeur est confinée à la paroi thoracique et aux tissus mous axiaux des enfants et des jeunes adultes. Elle est rarement signalée dans d'autres foyers et au sein de la population âgée.

Figure 1) Popliteal mass

Figure 2) Hematoxylin and eosin stain of the popliteal tumour. Original magnification ×66 (left); ×132 (right)

¹Department of Plastic Surgery; ²Department of Vascular Surgery, Royal Brisbane and Women's Hospital; ³Department of Surgery, University of Queensland; ⁴Department of Anatomical Pathology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

Correspondence: Dr Colin M Davis, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, Queensland, Australia 4029.

Telephone 614-2195-5606, e-mail colin_davis@health.qld.gov.au

TABLE 1
Differential diagnosis of popliteal fossa masses

Tissue type	Examples
Skin and subcutaneous tissue	Sebaceous cyst, carbuncle, lipomas, abscess, hemangiomas, skin malignancies, sarcomas, cellulitis
Muscle	Contusions of gastrocnemius or semimembranosus
Bursae	Synovial cysts (Baker), meniscal cysts, popliteal cystic tumours
Vascular	Varicocele, thrombophlebitis, arteriovenous malformations/fistulas, aneurysms, vascular tumours, deep vein thrombosis
Lymphatics	Enlarged popliteal nodes (secondary to tuberculosis adenopathy, distal infection or metastatic malignancy), lymphangioma
Nerves	Nerve sheath tumours (eg neurilemoma), peripheral nerve tumours (eg, perineuroma, PNET), neurofibroma, ganglion
Bone, periosteum and cartilage	Exostosis arising from epiphyseal cartilage of femur in children, medullary giant cell tumours, fibrosarcomas of the periosteum, osteomyelitis, fractures, chondroma

Data adapted from references 1 and 2. PNET Primitive neuroectodermal tumour

Figure 3) Schematic diagram of t(11;22)(q24;q12), observed in up to 85% of Ewing sarcoma/peripheral primitive neuroectodermal tumours. Adapted from reference 16

Microscopic findings showed a poorly differentiated tumour composed of small round cells with uniform nuclear features, occasional prominent nucleoli and indistinct cell borders (Figure 2). Occasional conspicuous Homer Wright-like rosettes were identified. The tumour was noted to have invaded fat, muscle and vascular tissue. Immunohistochemistry was positive for CD99, vimentin, BCL2 and CD56. Fluorescence in situ hybridization (FISH) studies were negative for the synovial sarcoma rearrangement (18q11.2) and Ewing sarcoma (ES) rearrangement (22q12). Due to classical morphology and immunohistochemistry staining, PNET was favoured while other differential diagnoses, such as Merkel cell tumour, lymphoma, rhabdomyosarcoma, synovial sarcoma, melanoma and carcinoma, were excluded. Because typical translocation could not be found in the FISH study, it was believed this may reflect a subgroup of peripheral PNETs (pPNETs), which lack this genetic change. The patient was referred for local radiation oncology and systemic chemotherapy.

DISCUSSION

Differential diagnosis of popliteal fossa masses

In adult patients, the most common cause of a popliteal mass is a Baker cyst. The differential diagnosis, however, is quite extensive. Classification according tissue type can assist with identifying the pathology (Table 1).

pPNETs

pPNETs are an extremely rare cause of a popliteal mass. Believed to originate from migrating embryonic cells of the neural crest (3), pPNETs are most commonly found in the chest wall and axial soft tissues (4,5), although they have been diagnosed in other areas including bone, extra-axial soft tissue and visceral tissues (6-11). Belonging to a family of ‘small round-cell tumours’, they are most frequently observed in children and young adults, but can occur at any age (12,13). Due to their aggressive nature, distant micrometastasis must always be

assumed to be present and, hence, all patients should receive adjuvant chemotherapy for systemic control (13,14).

pPNETs are commonly classed with ES and Askin’s tumour (pPNETs limited to the thoracopulmonary region) as members of the Ewing family of tumours (8,12,13,15-17). They have almost identical pathological, immunohistochemical and genetic features, with the main distinct difference being that tumours demonstrating neural differentiation are labelled pPNET while those that are undifferentiated are diagnosed as ES (3,12,15,18,19). Due to this subtle distinction between ES and pPNET, diagnosis can only be made with immunohistochemical, electron microscopy and molecular biological studies (19). The phenotypic expression distinction has, however, no clinical significance (15).

Epidemiologically, pPNET has a peak incidence in the second decade of life, with 80% of presentations <20 years of age (15,16). ES and pPNET account for 6% to 10% of primary malignant bone tumours following osteosarcoma as the second most common group of bone sarcomas in children (15,20). It is slightly more prevalent in males and more common in whites and Hispanic populations, while rare in African and Asian populations; the reasons for this are currently unknown (16,21).

Due to its insidious onset, patients often present with a large tumour, and as many as 20% to 25% already have detectable distant metastatic disease most commonly to the lung, bone and/or bone marrow (13,22-24). Nearly all, however, have micrometastases, as indicated by a 10% cure rate with local therapy alone (16). In addition to localized symptoms (pain, swelling, bleeding), systemic findings can occasionally occur including fever, elevated erythrocyte sedimentation rate, anemia and leukocytosis (15).

Radiologically, pPNETs often have a large soft tissue component (>5 cm on average) and show moderate enhancement with intravenous contrast, combined with nonenhancing necrotic areas (13). These necrotic areas tend to displace rather than encase adjacent organs. If they do involve adjacent bone, however, they tend to exhibit lytic/erosive change (13).

Macroscopically, pPNETs are usually soft, tan-white in colour, and frequently contain areas of hemorrhage and necrosis with calcification also noted occasionally (13,15). Microscopically, they typically consist of sheets of small monomorphic round dark cells with small hyperchromatic inconspicuous nuclei and scant cytoplasm (25). Extensive necrosis is usually present (16). A common finding in pPNET is the presence of Homer Wright rosettes (tumour cells arranged in a circle about a central fibrillary space), which is indicative of neural differentiation (7,15,26).

Because pPNET shows neuroepithelial differentiation, immunohistochemistry can be used to test for neurospecific proteins including NSE, Leu-7, enolase, synaptophysin, S-100 protein, PGP 9.5, secretogranin II, vimentin and keratin (19,27). Additionally, electron microscopy can also be used to reveal features of neural differentiation (eg, neurosecretory granules, neurofilaments and neurotubules) (28).

Eighty-five percent of tumours diagnosed as either ES or pPNET have the translocation t(11;22)(q24;q12) (15,16) (Figure 3). This translocation results in the division of two genes known as Friend

TABLE 2
Five-year local recurrence rates

Author (reference)	Patients, n	Five-year survival rate, %		
		Overall	If metastasized at diagnosis	If localized disease only at diagnosis
Baldini et al (18)	37	37	0 (n=11)	49 (n=24)
Kolb et al (22)	68		17.8 (four-year survival) (n=24)	89 (four-year survival) (n=44)
Smorenburg et al (25)	27	58	60 (n=10)	52 (n=17)
Martin and Brennan (35)	59	60	33	60
Fizazi et al (21)	182	41	9 (n=53)	54 (n=129)

leukemia virus integration 1 (*FLI-1*) gene and ES (*EWS*) gene. The *FLI-1* gene on 11q24 is a member of a large family of DNA-binding transcription factors that are implicated in the control of cellular proliferation, development and tumorigenesis (14,29). The *EWS* gene on 22q12 is believed to be involved in messenger RNA transcription (30). These two genes fuse to form a functional *EWS-FLI-1* gene, which results in abnormal cell proliferation and survival (16). This gene rearrangement is detected with FISH studies and is pathognomonic of ES/PNET (19). The remaining 15% have variants including 22q12,21q2 (10%), 7p22, 17q12 and 2q36 (<1%) (19).

Another highly specific test performed to identify a pPNET is immunohistochemical staining of an antigen for the *MIC2* gene. The product of the *MIC2* gene – CD99 – is a cell surface glycoprotein involved in cell adhesion. It is highly sensitive for pPNET; however, it has been known to occur in other tumours, such as 30% of carcinoid tumours and, thus, lacks specificity (26,31-33).

Treatment for pPNET consists primarily of systemic intensive multi-agent chemotherapy with surgery and/or radiotherapy for local control, inoperable tumours or lesions unresponsive to chemotherapy (16,22), although the relative efficacies of these local treatments remain controversial (18). Multi-agent chemotherapy is recommended due to the tumour's strong propensity for metastasis (18). In one study, chemotherapy was shown to improve five-year survival from 5% to 15% to 75%, with up to 50% having long-term cures (15). In 2003, Shamberger et al (34) suggested that the preferred treatment sequence is after initial biopsy for adjuvant chemotherapy with delayed resection after four courses of treatment. This is believed to avoid the need for radiotherapy (and associated complications).

Although study numbers are relatively small, five-year survival rates are approximately 40% to 60%, with patients with metastatic disease at diagnosis having a much poorer outcome well below 30% five-year survival (18,25,35) (Table 2). Consistently adverse prognostic factors include larger tumour size (>5 cm to 8 cm), metastasis at time of diagnosis and bone metastasis (9,18,25,36-38).

Several studies have reported a poorer prognosis with older patients (18,39); however, this finding is not consistent across all studies (40). A study by Verill et al (37) involving 59 patients showed that adults had a similar prognosis, with a 38% five-year survival rate (52% if localized). A reason proposed by Baldini et al (18) for more favourable outcomes in younger patients is that they have more bone marrow reserve to tolerate the long chemotherapy regimens that have been used. Five-year local recurrence rates are approximately 15% (18,35,41).

The incidence of pPNET is likely to be under-reported in the literature. Recent cytogenetic and immunohistochemical advances have enabled these tumours to be distinguished from other small, poorly differentiated round cell tumours such as neuroblastoma, rhabdomyosarcoma and lymphoma (42). Research investigating targeted molecular therapies is underway (43).

CONCLUSION

The present case demonstrates a rare pathology not only for this age group but also for a popliteal fossa mass. It is always important to consider the rare and serious causes when diagnosing a lesion.

CONSENT: Informed, written consent was not obtained from the patient for publication of this case report and accompanying images. There are, however, no identifiable images of the patient used in this article.

DISCLOSURES: The authors have no financial disclosures or conflicts of interest to declare.

AUTHORS' CONTRIBUTIONS: CD and AC performed the literature review and drafted the manuscript. TT performed the histological analysis and critically reviewed the manuscript. DS, SS and VH operated on and supervised the care of the patient and critically drafted the manuscript. All authors read and approved the final manuscript.

REFERENCES

1. Ghaly RE. A posterior tibial nerve neurilemoma unrecognized for 10 years: Case report. *Neurosurgery* 2001;48:668-72.
2. Collins RD. *Differential Diagnosis in Primary Care*, 4th edn. Philadelphia: Williams & Wilkins, 2007.
3. Dehner LP. Primitive neuroectodermal tumor and Ewing's sarcoma. *Am J Surg Pathol* 1993;17:1-13.
4. Askin FB, Rosai J, Sibley RK, Dehner LP, McAlister WH. Malignant small cell tumor of the thoracopulmonary region in childhood: A distinctive clinicopathologic entity of uncertain histogenesis. *Cancer* 1979;43:2438-51.
5. Schweigert M, Meyer C, Wolf F, Stein HJ. Peripheral primitive neuroectodermal tumor of the thymus. *Interact Cardiovasc Thorac Surg* 2011;12:303-5.
6. O'Sullivan MJ, Perlman EJ, Furman J, Humphrey PA, Dehner LP, Pfeifer JD. Visceral primitive peripheral neuroectodermal tumors: A clinicopathologic and molecular study. *Hum Pathol* 2001;32:1109-15.
7. Vindal A, Kakar AK. Primary primitive neuroectodermal tumor of the breast. *J Clin Oncol* 2010;28:e453-5.
8. Harzy T, Elmrini A, Znati K, Amarti A, Bono W. Metastatic peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the knee mimicking a popliteal cyst in an adult patient. *J Clin Rheumatol* 2009;15:150.
9. Marques M, Cardoso H, Barroca H, Lopes J, Macedo G. Peripheral primitive neuroectodermal tumour of the liver: A case report and review of the literature. *Gastroenterol Hepatol* 2011;34:611-3.
10. Kahn AG, Avagnina A, Nazar J, Elsner B. Primitive neuroectodermal tumor of the lung. *Arch Pathol Lab Med* 2001;125:397-9.
11. Paruliya D, Sharma S, Gokhroo S, Yadav SS, Sharma KK, Sadasukhi TC. Primary neuroectodermal tumor of penis (PNET) – a case report. *Urology* 2007;70:811 e9-10.
12. Grier HE. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. *Pediatr Clin North Am* 1997;44:991-1004.
13. Hari S, Jain TP, Thulker S, Bakhshi S. Imaging features of peripheral primitive neuroectodermal tumours. *Br J Radiol* 2008;81:975-83.
14. Sharrocks AD, Brown AL, Ling Y, Yates PR. The ETS-domain transcription factor family. *Int J Biochem Cell Biol* 1997;29:1371-87.
15. Robbins SL. *Robbins and Cotran Pathologic Basis of Disease*. Philadelphia: Saunders/Elsevier 2010:1232-3.

16. de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. *J Clin Oncol* 2000;18:204-13.
17. Parikh M, Samujh R, Kanojia RP, Mishra AK, Sodhi KS, Bal A. Peripheral primitive neuroectodermal tumor of the chest wall in childhood: Clinico-pathological significance, management and literature review. *Chang Gung Med J* 2011;34:213-7.
18. Baldini EH, Demetri GD, Fletcher CD, Foran J, Marcus KC, Singer S. Adults with Ewing's sarcoma/primitive neuroectodermal tumor: Adverse effect of older age and primary extrasosseous disease on outcome. *Ann Surg* 1999;230:79-86.
19. Suarez Antelo J, Rodriguez Garcia C, Montero Martinez C, Verea Hernando H. [Pulmonary Ewing sarcoma/primitive neuroectodermal tumor: A case report and a review of the literature]. *Arch Bronconeumol* 2010;46:44-6.
20. Takahashi D, Nagayama J, Nagatoshi Y, et al. Primary Ewing's sarcoma family tumors of the lung a case report and review of the literature. *Jpn J Clin Oncol* 2007;37:874-7.
21. Fizazi K, Dohollou N, Blay JY, et al. Ewing's family of tumors in adults: Multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. *J Clin Oncol* 1998;16:3736-43.
22. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. *J Clin Oncol* 2003;21:3423-30.
23. Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. *J Clin Oncol* 2001;19:870-80.
24. Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: Evaluation of combination ifosfamide and etoposide – a Children's Cancer Group and Pediatric Oncology Group study. *J Clin Oncol* 2004;22:2873-6.
25. Smorenburg CH, van Groenigen CJ, Meijer OW, Visser M, Boven E. Ewing's sarcoma and primitive neuroectodermal tumour in adults: Single-centre experience in The Netherlands. *Neth J Med* 2007;65:132-6.
26. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. *Cancer* 1991;67:1886-93.
27. Khong PL, Chan GC, Shek TW, Tam PK, Chan FL. Imaging of peripheral PNET: Common and uncommon locations. *Clin Radiol* 2002;57:272-7.
28. Sallustio G, Pirronti T, Lasorella A, Natale L, Bray A, Marano P. Diagnostic imaging of primitive neuroectodermal tumour of the chest wall (Askin tumour). *Pediatr Radiol* 1998;28:697-702.
29. Hromas R, Klemsz M. The ETS oncogene family in development, proliferation and neoplasia. *Int J Hematol* 1994;59:257-65.
30. Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: Interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. *Mol Cell Biol* 1998;18:1489-97.
31. Ko K, Kim EA, Lee ES, Kwon Y. Primary primitive neuroectodermal tumor of the breast: A case report. *Korean J Radiol* 2009;10:407-10.
32. Tamura G, Sasou S, Kudoh S, et al. Primitive neuroectodermal tumor of the breast: Immunohistochemistry and fluorescence in situ hybridization. *Pathol Int* 2007;57:509-12.
33. Weidner N, Tjoe J. Immunohistochemical profile of monoclonal antibody O13: Antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. *Am J Surg Pathol* 1994;18:486-94.
34. Rao BN, Hayes FA, Thompson EI, et al. Chest wall resection for Ewing's sarcoma of the rib: An unnecessary procedure. *Ann Thorac Surg* 1988;46:40-4.
35. Martin RC II, Brennan MF. Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: Predictors of survival? *Arch Surg* 2003;138:281-5.
36. Terrier P, Llombart-Bosch A, Contesso G. Small round blue cell tumors in bone: Prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. *Semin Diagn Pathol* 1996;13:250-7.
37. Verrill MW, Judson IR, Harmer CL, Fisher C, Thomas JM, Wiltshaw E. Ewing's sarcoma and primitive neuroectodermal tumor in adults: Are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children? *J Clin Oncol* 1997;15:2611-21.
38. Gobel V, Jurgens H, Etschler G, et al. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. *J Cancer Res Clin Oncol* 1987;113:187-91.
39. Kinsella TJ, Miser JS, Waller B, et al. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. *Int J Radiat Oncol Biol Phys* 1991;20:389-95.
40. Wilkins RM, Pritchard DJ, Burgert EO Jr, Unni KK. Ewing's sarcoma of bone. Experience with 140 patients. *Cancer* 1986;58:2551-5.
41. Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study. *J Clin Oncol* 1990;8:1664-74.
42. Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: A study of 66 genetically confirmed cases. *Am J Surg Pathol* 2005;29:1025-33.
43. Maksimenko A, Lambert G, Bertrand JR, Fattal E, Couvreur P, Malvy C. Therapeutic potentialities of EWS-Flt-1 mRNA-targeted vectorized antisense oligonucleotides. *Ann N Y Acad Sci* 2003;1002:72-7.